Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| NATIONAL VACCINATION PROGRAMME for HepB: only for children of HBsAg-positive mothers |
- Intramuscular
-
0 days
up to
2 days
[1]
[2]
[3]
[4]
First vaccination at birth (within 48 hours after birth), preferably concomitantly with hepatitis B immunoglobulin: HBvaxPRO: 5 mcg/dose once only. Combined with hepatitis B immunoglobulines.
Follow-on vaccinations with combined DPTP-HiB-HepB vaccine at 2-3-5-11 months
|
| Hepatitis B vaccination |
- Intramuscular
-
0 years
up to
16 years
[2]
[3]
ENGERIX: 10 mcg/dose HBVAXPRO: 5 mcg/dose
VACCINATION SCHEDULE: First vaccination: at any time, not related to the age Second vaccination: 1 month after the first vaccination third vaccination: 6 months after the first vaccination
Accelerated schedule: First vaccination: at any time, not related to the age Second vaccination: 1 month after the first vaccination third vaccination: 2 months after the first vaccination fourth vaccination: 12 months after the first vaccination
Administer the vaccine in adults and children intramuscularly in the deltoid. Administer intramuscularly in neonates, infants and young children (< 3 yrs) in the anterolateral thigh.
-
16 years
up to
18 years
[2]
[3]
ENGERIX: 20 mcg/dose HBVAXPRO: 10 mcg/dose
VACCINATION SCHEDULE: First vaccination: at any time, not related to the age Second vaccination: 1 month after the first vaccination third vaccination: 6 months after the first vaccination
Accelerated schedule: First vaccination: at any time, not related to the age Second vaccination: 1 month after the first vaccination third vaccination: 2 months after the first vaccination fourth vaccination: 12 months after the first vaccination
Administer the vaccine in adults and children intramuscularly in the deltoid
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
In very premature children (≤ 28 weeks pregnancy): apnoea.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
In primary immunization of very premature children (≤ 28 weeks of pregnancy), take account of the risk of apnoea and the need to monitor respiratory function for 48-72 hours, especially in children whose anamnesis includes a respiratory system that was not yet fully developed. Given the importance of vaccinating, the vaccination should however not be postponed or withheld from these children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
VIRAL VACCINES
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Encephalitis vaccines |
|
|
|
J07BA02
|
|
|
|
J07BA01
|
| Influenza vaccines |
|
|
|
J07BB02
|
| Hepatitis vaccines |
|
|
|
J07BC20
|
|
|
|
J07BC02
|
| Poliomyelitis vaccines |
|
|
|
J07BF03
|
| Rota virus diarrhea vaccines |
|
|
|
J07BH01
|
| Varicella zoster vaccines |
|
|
|
J07BK01
|
| Yellow fever vaccines |
|
|
|
J07BL01
|
| Papillomavirus vaccines |
|
|
|
J07BM03
|
|
|
|
J07BM02
|
| Other viral vaccines |
|
|
|
J07BX04
|
References
-
RIVM , Richtlijn hepatitis B, Juli 2023, https://lci.rivm.nl/richtlijnen/hepatitis-b
-
GlaxoSmithKline BV, SPC Engerix B Junior RVG 24290, www.cbg-meb.nl, (geraadpleegd 30 okt 2009), http://db.cbg-meb.nl/IB-teksten/h24290.pdf
-
MSD Vaccins, SPC HBVAXPRO (EU/1/01/183/001;007;008;018;019) 30-03-2017, www.ema.europa.eu
-
RIVM, Bevolkingsonderzoek Prenatale Screening Infectieziekten en Erytrocytenimmunisatie, www.rivm.nl, april 2021
Therapeutic Drug Monitoring
Overdose